Towards disease modification in osteoarthritis
- PMID: 37196976
- DOI: 10.1016/j.joca.2023.05.002
Towards disease modification in osteoarthritis
Abstract
In December 2022, Gerwin et al published in Nature Medicine that the C-terminal portion of angiopoietin-like 3, called LNA043, has chondroprotective and cartilage-regenerative properties. Molecular data from an experimental medicine phase I study suggested potential efficacy in humans. Here, we respond to and complement a commentary from Vincent and Conaghan and discuss unresolved issues and the potential of this molecule as a disease-modifying osteoarthritis drug.
Copyright © 2023. Published by Elsevier Ltd.
Conflict of interest statement
Conflicts of interest F.D.A. has received consultancy fees from UCB and Biosplice Therapeutics. C.D.B. has received research grant funding through the institution from Biosplice Therapeutics, and consultancy fees from UCB, Galapagos, and Cellthrion Healthcare.
Comment on
-
Angiopoietin-like 3-derivative LNA043 for cartilage regeneration in osteoarthritis: a randomized phase 1 trial.Nat Med. 2022 Dec;28(12):2633-2645. doi: 10.1038/s41591-022-02059-9. Epub 2022 Dec 1. Nat Med. 2022. PMID: 36456835 Free PMC article. Clinical Trial.
-
Are pro-regenerative therapies the future of osteoarthritis disease modification?Osteoarthritis Cartilage. 2023 Sep;31(9):1152-1153. doi: 10.1016/j.joca.2023.05.003. Epub 2023 May 15. Osteoarthritis Cartilage. 2023. PMID: 37196977 No abstract available.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical